A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB
Status:
NOT_YET_RECRUITING
Trial end date:
2030-01-01
Target enrollment:
Participant gender:
Summary
This study is divided into two parts. Part A is a multicenter, randomized, double-blind, placebo controlled phase Ill clinical trial, designed to evaluate the efficacy and safety of ZM-H1505R in combination with NAs versus NAs monotherapy with HBV DNA 50 IU/mL and are HBeAg positive who have received NAs monotherapy for at least 12months.Part B is an open-label extension and follow-up period designed to evaluate the long-term safety and efficacy of ZM-H1505R in combination with NAs.